Effective chimeric antigen receptor T cells against SARS-CoV-2

Area of Science:

• Immunology
• Molecular Biology
• Virology

Background:

• Current COVID-19 treatments primarily rely on vaccines targeting the SARS-CoV-2 spike protein S1.
• There is a need for alternative therapeutic strategies to combat SARS-CoV-2 infection.

Purpose of the Study:

• To investigate the potential of chimeric antigen receptors (CARs) engineered into T-cells (CAR-Ts) as a novel therapeutic approach for COVID-19.
• To evaluate the efficacy of SARS-CoV-2 specific CAR-Ts in recognizing and eliminating infected cells.

Main Methods:

• Generation of CAR-T cells targeting the SARS-CoV-2 receptor-binding domain (RBD) and S1 protein.
• In vitro assessment of CAR-T cell activation, effector function, and target cell killing.
• In vivo evaluation of CAR-T cell efficacy in a mouse model.

Main Results:

• CAR-T recognition of SARS-CoV-2 antigens induced T-cell activation and effector molecule release (IFN-γ, granzyme B, perforin, Fas-ligand).
• CAR-Ts demonstrated potent in vitro killing of target cells expressing RBD, S1 peptide, or S1 protein.
• Cytolysis was primarily mediated by the granzyme B/perforin pathway, with varying efficacy based on CAR hinge region length.
• In vivo studies confirmed CAR-T mediated killing of S1-expressing cells in mice.

Conclusions:

• The development of SARS-CoV-2 specific CAR-Ts represents a promising "living vaccine" strategy for COVID-19 treatment.
• CAR-T cell therapy offers a potential alternative or adjunct to current vaccination and treatment modalities.